Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) - Research analysts at Cantor Fitzgerald dropped their FY2025 EPS estimates for shares of Zai Lab in a research report issued on Monday, June 23rd. Cantor Fitzgerald analyst L. Watsek now expects that the company will earn ($0.94) per share for the year, down from their previous forecast of ($0.82). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Zai Lab's current full-year earnings is ($2.58) per share. Cantor Fitzgerald also issued estimates for Zai Lab's FY2026 earnings at $0.27 EPS.
Other equities analysts have also issued research reports about the company. Bank of America reiterated a "neutral" rating and issued a $36.10 target price (up previously from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd. JPMorgan Chase & Co. lifted their price objective on shares of Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a research report on Thursday, March 13th. Finally, Scotiabank started coverage on shares of Zai Lab in a research report on Friday, March 7th. They set a "sector outperform" rating and a $55.00 target price for the company.
Check Out Our Latest Research Report on ZLAB
Zai Lab Trading Up 4.4%
ZLAB opened at $37.58 on Wednesday. The firm has a market cap of $4.15 billion, a price-to-earnings ratio of -15.09 and a beta of 0.96. Zai Lab has a 12 month low of $16.01 and a 12 month high of $44.34. The stock has a fifty day moving average price of $33.04 and a 200-day moving average price of $30.93.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.05. The company had revenue of $106.49 million during the quarter, compared to the consensus estimate of $118.40 million. Zai Lab had a negative net margin of 60.26% and a negative return on equity of 33.35%.
Hedge Funds Weigh In On Zai Lab
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC acquired a new stake in Zai Lab during the 1st quarter valued at approximately $1,073,000. MPM Bioimpact LLC boosted its holdings in Zai Lab by 4.2% in the first quarter. MPM Bioimpact LLC now owns 833,659 shares of the company's stock valued at $30,128,000 after purchasing an additional 33,659 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new stake in Zai Lab during the 1st quarter worth about $12,649,000. Cubist Systematic Strategies LLC raised its stake in shares of Zai Lab by 29.0% during the 1st quarter. Cubist Systematic Strategies LLC now owns 93,645 shares of the company's stock valued at $3,384,000 after buying an additional 21,026 shares during the last quarter. Finally, Royal Bank of Canada lifted its holdings in shares of Zai Lab by 214.3% in the 1st quarter. Royal Bank of Canada now owns 13,771 shares of the company's stock valued at $498,000 after buying an additional 9,390 shares during the period. Institutional investors and hedge funds own 41.65% of the company's stock.
Insider Activity at Zai Lab
In other news, insider Frazor Titus Edmondson III sold 4,369 shares of the firm's stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $35.89, for a total value of $156,803.41. Following the completion of the transaction, the insider now directly owns 27,217 shares in the company, valued at $976,818.13. This trade represents a 13.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Ying Du sold 5,808 shares of Zai Lab stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $35.89, for a total value of $208,449.12. Following the sale, the chief executive officer now directly owns 476,046 shares of the company's stock, valued at $17,085,290.94. This trade represents a 1.21% decrease in their position. The disclosure for this sale can be found here. Insiders sold 141,021 shares of company stock valued at $4,257,755 in the last three months. 4.96% of the stock is owned by insiders.
About Zai Lab
(
Get Free Report)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zai Lab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.
While Zai Lab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
